First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet
chemotherapy given as first line treatment in terms of progression free survival in selected
NSCLC patients with the objective of demonstrating non-inferiority.